Shili Xu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4757580/publications.pdf

Version: 2024-02-01

34 papers	2,064 citations	361413 20 h-index	434195 31 g-index
35 all docs	35 docs citations	35 times ranked	3869 citing authors

#	Article	IF	Citations
1	Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. Nature Communications, 2016, 7, 11457.	12.8	386
2	Small Molecule Inhibitors of CXCR4. Theranostics, 2013, 3, 47-75.	10.0	230
3	Protein disulfide isomerase: a promising target for cancer therapy. Drug Discovery Today, 2014, 19, 222-240.	6.4	223
4	Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16348-16353.	7.1	200
5	Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (Stat3) Protein. Journal of Medicinal Chemistry, 2012, 55, 6645-6668.	6.4	168
6	Discovery of a Novel Orally Active Small-Molecule gp130 Inhibitor for the Treatment of Ovarian Cancer. Molecular Cancer Therapeutics, 2013, 12, 937-949.	4.1	95
7	A Tumor Agnostic Therapeutic Strategy for Hexokinase 1â€“Null/Hexokinase 2â€“Positive Cancers. Cancer Research, 2019, 79, 5907-5914.	0.9	71
8	Chronic IL-1Î²-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer. Scientific Reports, 2020, 10, 377.	3.3	65
9	gp130: a promising drug target for cancer therapy. Expert Opinion on Therapeutic Targets, 2013, 17, 1303-1328.	3.4	59
10	Giant Magnetoelastic Effect Enabled Stretchable Sensor for Self-Powered Biomonitoring. ACS Nano, 2022, 16, 6013-6022.	14.6	59
11	Small-Molecule Inhibitors of p53-MDM2 Interaction: the 2006-2010 Update. Current Pharmaceutical Design, 2011, 17, 536-559.	1.9	56
12	Repositioning HIV-1 Integrase Inhibitors for Cancer Therapeutics: 1,6-Naphthyridine-7-carboxamide as a Promising Scaffold with Drug-like Properties. Journal of Medicinal Chemistry, 2012, 55, 9492-9509.	6.4	46
13	An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1â˜HK2+ Multiple Myeloma. Cancer Research, 2019, 79, 2748-2760.	0.9	41
14	Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6842-6847.	7.1	40
15	Biological evaluation of Paclitaxel-peptide conjugates as a model for MMP2-targeted drug delivery. Cancer Biology and Therapy, 2010, 9, 192-203.	3.4	36
16	Stabilization of MDA-7/IL-24 for colon cancer therapy. Cancer Letters, 2013, 335, 421-430.	7.2	36
17	Hexokinase 2 discerns a novel circulating tumor cell population associated with poor prognosis in lung cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	36
18	Inhibition of protein disulfide isomerase in glioblastoma causes marked downregulation of DNA repair and DNA damage response genes. Theranostics, 2019, 9, 2282-2298.	10.0	35

#	Article	IF	Citations
19	Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer. British Journal of Cancer, 2015, 113, 242-251.	6.4	27
20	A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers. Cancer & Metabolism, 2018, 6, 7.	5.0	25
21	Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression. Theranostics, 2020, 10, 829-840.	10.0	21
22	Hexokinase 2 Is Targetable for HK1-Negative, HK2-Positive Tumors from a Wide Variety of Tissues of Origin. Journal of Nuclear Medicine, 2019, 60, 212-217.	5.0	18
23	Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism. Cell Chemical Biology, 2020, 27, 197-205.e6.	5.2	16
24	Loss of Survivin in the Prostate Epithelium Impedes Carcinogenesis in a Mouse Model of Prostate Adenocarcinoma. PLoS ONE, 2013, 8, e69484.	2.5	14
25	Development and Application of FASA, a Model for Quantifying Fatty Acid Metabolism Using Stable Isotope Labeling. Cell Reports, 2018, 25, 2919-2934.e8.	6.4	13
26	A Review on PARP1 Inhibitors: Pharmacophore Modeling, Virtual and Biological Screening Studies to Identify Novel PARP1 Inhibitors. Current Topics in Medicinal Chemistry, 2014, 14, 2020-2030.	2.1	11
27	Synthesis and SAR studies of marine natural products maâ€™edamines A, B and their analogues. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5135-5139.	2.2	8
28	Identification, synthesis and evaluation of CSF1R inhibitors using fragment based drug design. Computational Biology and Chemistry, 2019, 80, 374-383.	2.3	7
29	Positron Emission Tomography Tracer Design of Targeted Synthetic Peptides via ‹sup›18‹/sup›F-Sydnone Alkyne Cycloaddition. Bioconjugate Chemistry, 2021, 32, 2073-2082.	3.6	7
30	Comparison of the Efficacy and Sensitivity of Alternative PET Reporter Gene/PET Reporter Probe Systems That Minimize Biological Variables. Methods in Molecular Biology, 2020, 2126, 177-190.	0.9	1
31	A chemical lipid modification of recombinant preS antigen to study the mechanism of HBV attachment to the host cell. Journal of Biotechnology, 2008, 137, 8-13.	3.8	0
32	Abstract C148: SC144: The first orally active small molecule gp130 inhibitor for the treatment of ovarian cancer.. , 2011, , .		0
33	Abstract 5513: Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase (PDI) for ovarian cancer treatment.. , 2013, , .		0
34	Abstract 1812: XCE853: A novel PDI inhibitor that inhibits proliferation of human tumor cellsin vitro,ex-vivoandin vivo. , 2014, , .		0